Shaw L M, Altman R, Thompson B C, Fields L
Clin Chem. 1985 Apr;31(4):616-9.
We investigated the influence of the following factors on the binding of disopyramide to serum proteins: method of drug quantification [enzyme immunoassay (EMIT) compared with liquid chromatography (HPLC)], separation technique (ultrafiltration vs equilibrium dialysis), temperature, pH, and total concentration of disopyramide. EMIT and HPLC measurements of disopyramide in ultrafiltrates prepared from 50 sera agreed well: EMIT = 1.046 HPLC + 0.042, (r = 0.928, SEE = 0.04 mg/L). Free disopyramide concentrations in ultrafiltrates of dialyzed sera were similar to those measured in the corresponding dialysates by the EMIT method for 30 patients' sera: ultrafiltrate of serum retentate = 1.053 dialysate + 0.042. Concentrations of free [14C]disopyramide were little affected by temperature. The concentration of free disopyramide decreased as the pH was increased from 7.0 to 7.8. The concentration of free disopyramide, as determined by ultrafiltration, is strongly and directly related to total drug concentration. In the sera of 50 cardiac patients receiving chronic therapy with disopyramide and with total disopyramide concentrations of 0.5 to 5.8 mg/L, the proportion of free disopyramide ranged from 16 to 54%.
药物定量方法[酶免疫测定法(EMIT)与液相色谱法(HPLC)比较]、分离技术(超滤与平衡透析)、温度、pH值以及丙吡胺的总浓度。用50份血清制备的超滤液中丙吡胺的EMIT和HPLC测量结果吻合良好:EMIT = 1.046 HPLC + 0.042,(r = 0.928,标准误 = 0.04 mg/L)。对于30例患者的血清,透析血清超滤液中游离丙吡胺浓度与通过EMIT法在相应透析液中测得的浓度相似:血清截留物超滤液 = 1.053透析液 + 0.042。游离[14C]丙吡胺的浓度受温度影响较小。随着pH值从7.0升高到7.8,游离丙吡胺的浓度降低。通过超滤测定的游离丙吡胺浓度与总药物浓度呈强烈的直接相关。在50例接受丙吡胺长期治疗且总丙吡胺浓度为0.5至5.8 mg/L的心脏病患者血清中,游离丙吡胺的比例为16%至54%。